Cardinal Health
CAH
232.16
-1.28
-0.55%
Cardinal Health
US · CAH
#429 by market cap
Listed 1970
232.16
-1.28
-0.55%
Live - 5344 symbols - heartbeat 45s ago
· 2026-10-08 07:00
Pre-market
227.75
-1.90%
After-hours
232.90
+0.32%
- Market cap
- 53.76B
- P/E (TTM)i
- 32.11
- P/Bi
- -18.65
- EPSi
- 7.23
- Div yieldi
- 0.88%
- 52W posi
- 76%
Reader sentiment
Are you bullish or bearish on CAH?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 5.10, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +14.23% YoY
Margins
- Gross margin
- 3.84%
- Operating margin
- 1.25%
- Net margin
- 0.67%
Key ratios & quality
- Enterprise valuei
- 57.79B
- PEG ratioi
- 0.44
- Altman Z-Scorei
- 5.10
PEG uses trailing P/E against the 3-year net income growth rate (73.18%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 145.53B | 152.92B | 162.47B | 181.33B | 204.98B | 226.83B | 222.58B | 254.25B |
| Gross profit | 6.83B | 6.87B | 6.78B | 6.48B | 6.87B | 7.41B | 8.17B | 9.77B |
| Selling & admin expenses | 4.48B | 4.57B | 4.53B | 4.51B | 4.80B | 5.00B | 5.38B | 6.13B |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 1.73B | 1.77B | 1.79B | 1.65B | 1.79B | 2.13B | 2.32B | 3.17B |
| Pretax profit | 1.75B | -3.77B | 323.00M | -784.00M | 663.00M | 1.20B | 2.10B | 2.17B |
| Tax | 386.00M | -79.00M | -289.00M | 153.00M | 332.00M | 348.00M | 532.00M | 469.00M |
| Net profit | 1.37B | -3.69B | 612.00M | -937.00M | 331.00M | 853.00M | 1.57B | 1.71B |
| Basic EPS | 5 | -13 | 2 | -3 | 1 | 3 | 6 | 7 |
| Diluted EPS | 4.53 | -12.61 | 2.08 | -3.37 | 1.26 | 3.45 | 6.45 | 7.23 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 54.88B | 60.16B | 64.01B | 65.63B | 60.94B | 63.67B |
| Gross profit | 2.12B | 2.20B | 2.32B | 2.40B | 2.50B | 2.56B |
| Selling & admin expenses | 1.32B | 1.48B | 1.46B | 1.50B | 1.54B | 1.63B |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 656.00M | 585.00M | 754.00M | 763.00M | 842.00M | 814.00M |
| Pretax profit | 665.00M | 384.00M | 598.00M | 630.00M | 392.00M | 554.00M |
| Tax | 157.00M | 141.00M | 144.00M | 159.00M | 12.00M | 154.00M |
| Net profit | 508.00M | 243.00M | 454.00M | 471.00M | 380.00M | 400.00M |
| Basic EPS | 2 | 1 | 2 | 2 | 2 | 2 |
| Diluted EPS | 2.10 | 1.00 | 1.88 | 1.97 | 1.69 | 1.70 |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 25.75B | 25.94B | 31.05B | 32.94B | 33.74B | 34.88B | 36.37B | 38.75B |
| Cash & ST investments | 2.53B | 2.77B | 3.41B | 4.72B | 4.08B | 5.13B | 3.87B | 4.86B |
| Inventory | 12.82B | 13.20B | 14.59B | 15.64B | 16.12B | 14.96B | 16.83B | 17.30B |
| Total assets | 40.96B | 40.77B | 44.45B | 43.88B | 43.35B | 45.12B | 53.12B | 57.30B |
| Total current liabilities | 24.11B | 23.62B | 27.62B | 30.55B | 33.74B | 35.64B | 38.90B | 43.90B |
| Short-term debt | 452.00M | 10.00M | 871.00M | 580.00M | 792.00M | 434.00M | 550.00M | 1.88B |
| Long-term debt | 7.58B | 6.77B | 5.37B | 4.74B | 3.91B | 4.66B | 7.98B | 7.00B |
| Total liabilities | 34,633,000,000.00 | 38,974,000,000.00 | 42,659,000,000.00 | 44,584,000,000.00 | 46,306,000,000.00 | 48,333,000,000.00 | 55,756,000,000.00 | 60,023,000,000.00 |
| Total equity | 6.33B | 1.79B | 1.79B | -706.00M | -2.96B | -3.21B | -2.63B | -2.72B |
| Retained earnings | 5.43B | 1.17B | 1.21B | -280.00M | -642.00M | -286.00M | 783.00M | 2.01B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 34.60B | 36.37B | 38.54B | 39.23B | 38.06B | 38.75B |
| Cash & ST investments | 3.33B | 3.87B | 4.59B | 2.78B | 3.94B | 4.86B |
| Inventory | 16.16B | 16.83B | 17.56B | 20.12B | 18.01B | 17.30B |
| Total assets | 49.87B | 53.12B | 55.23B | 58.08B | 56.69B | 57.30B |
| Total current liabilities | 36.66B | 38.90B | 40.27B | 43.31B | 41.99B | 43.90B |
| Short-term debt | 543.00M | 550.00M | 52.00M | 680.00M | 671.00M | 1.88B |
| Long-term debt | 7.14B | 7.98B | 8.98B | 8.35B | 8.25B | 7.00B |
| Total liabilities | 51,769,000,000.00 | 55,756,000,000.00 | 57,959,000,000.00 | 60,783,000,000.00 | 59,361,000,000.00 | 60,023,000,000.00 |
| Total equity | -1.90B | -2.63B | -2.73B | -2.70B | -2.67B | -2.72B |
| Retained earnings | 664.00M | 783.00M | 1.12B | 1.46B | 1.73B | 2.01B |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 2.72B | 1.96B | 2.43B | 3.18B | 2.84B | 3.76B | 2.40B | 5.17B |
| Depreciation & amortization | 1.00B | 913.00M | 783.00M | 692.00M | 692.00M | 710.00M | 790.00M | 956.00M |
| Free cash flow | 2.39B | 1.59B | 2.03B | 2.79B | 2.36B | 3.25B | 1.85B | 4.53B |
| Dividends paid | -577.00M | -569.00M | -573.00M | -559.00M | -525.00M | -499.00M | -494.00M | -491.00M |
| Stock buybacks / issuance | -600.00M | -350.00M | -200.00M | -1.00B | -2.00B | -750.00M | -765.00M | -1.36B |
| Ending cash balance | 2.53B | 2.77B | 3.41B | 4.75B | 4.08B | 5.13B | 3.87B | 4.86B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 2.92B | 1.52B | 973.00M | 686.00M | 1.82B | 1.69B |
| Depreciation & amortization | 207.00M | 209.00M | 233.00M | 234.00M | 248.00M | 241.00M |
| Free cash flow | 2.79B | 1.29B | 865.00M | 555.00M | 1.68B | 1.43B |
| Dividends paid | -124.00M | -120.00M | -129.00M | -122.00M | -120.00M | -120.00M |
| Stock buybacks / issuance | -375.00M | 0 | -375.00M | -383.00M | -250.00M | -350.00M |
| Ending cash balance | 3.33B | 3.87B | 4.59B | 2.78B | 3.94B | 4.86B |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 22.01 | -91.07 | 34.13 | -172.46 | -- | -- | -- | -- |
| ROA %i | 3.37 | -9.04 | 1.43 | -2.11 | 0.60 | 1.92 | 3.18 | 3.10 |
| ROIC %i | 10.82 | -30.21 | 8.95 | -13.02 | -- | -- | -- | -- |
| 5-year avg ROE %i | 17.35 | -4.70 | -2.33 | -40.87 | -- | -- | -- | -- |
| EBIT margin %i | 1.41 | -2.31 | 0.31 | -0.34 | 0.36 | 0.55 | 1.04 | 0.99 |
| FCF / sales %i | 1.65 | 1.04 | 1.25 | 1.51 | 1.15 | 1.43 | 0.83 | 1.78 |
| Current ratioi | 1.07 | 1.10 | 1.12 | 1.08 | 1.00 | 0.98 | 0.94 | 0.88 |
| Quick ratioi | 0.46 | 0.47 | 0.45 | 0.50 | 0.45 | 0.48 | 0.44 | 0.43 |
| Debt / assetsi | 19.61 | 16.62 | 14.03 | 12.11 | 10.84 | 11.29 | 16.05 | 15.51 |
| LT debt / equityi | 119.77 | 378.14 | 299.55 | -- | -- | -- | -- | -- |
| Interest coveragei | 6.96 | -14.85 | 2.79 | -4.16 | 7.86 | 24.55 | 10.77 | 7.25 |
| Revenue CAGR (3Y) %i | 6.19 | 5.57 | 5.90 | 7.60 | 10.26 | 11.77 | 7.07 | 7.44 |
| Net income CAGR (3Y) %i | -1.52 | -- | 33.64 | -- | -- | 11.72 | -- | 73.18 |
| FCF CAGR (3Y) %i | -1.51 | 25.75 | -5.23 | 5.21 | 14.24 | 17.02 | -12.78 | 24.18 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -- | -- | -- |
| ROA %i | 3.25 | 3.18 | 3.25 | 3.16 | 2.92 | 3.10 |
| ROIC %i | -- | -- | -- | -- | -- | -- |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 1.02 | 1.04 | 1.03 | 1.06 | 0.94 | 0.99 |
| FCF / sales %i | 1.10 | 0.83 | 1.90 | 2.25 | 1.75 | 1.78 |
| Current ratioi | 0.94 | 0.94 | 0.96 | 0.91 | 0.91 | 0.88 |
| Quick ratioi | 0.44 | 0.44 | 0.46 | 0.38 | 0.42 | 0.43 |
| Debt / assetsi | 15.40 | 16.05 | 16.35 | 15.54 | 15.73 | 15.51 |
| LT debt / equityi | -- | -- | -- | -- | -- | -- |
| Interest coveragei | 15.05 | 10.77 | 9.21 | 8.21 | 6.84 | 7.25 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Pharmaceutical and Specialty Solutions is the largest reported line at 92.36% of revenue, across 4 reported segments.
- The next-largest line, Global Medical Products and Distribution (GMPD), is a distant second at 5.00% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Pharmaceutical and Specialty Solutions92.36%
Global Medical Products and Distribution (GMPD)5.00%
Other2.67%
Region
United States99.37%
International0.67%
Quote time 2026-10-08 07:00:05 · For reference only, not investment advice and not tailored to your situation.